Certain supplemental information not included in the press release

EX-99.2 3 dex992.htm CERTAIN SUPPLEMENTAL INFORMATION NOT INCLUDED IN THE PRESS RELEASE Certain supplemental information not included in the press release

EXHIBIT 99.2

MERCK & CO., INC.

CONSOLIDATED STATEMENT OF OPERATIONS

GAAP TO NON-GAAP RECONCILIATION

SECOND QUARTER 2009

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 2c


	GAAP			Restructuring Costs ⁽¹⁾		Merger-Related Costs ⁽²⁾		Adjustment Subtotal			Non-GAAP
Sales	$	5,899.9						$	—		$	5,899.9

Materials and production		1,353.9		47.1					47.1			1,306.8

Marketing and administrative		1,729.5				43.6			43.6			1,685.9

Research and development		1,395.3		107.8					107.8			1,287.5

Restructuring costs		37.4		37.4					37.4			—

Equity income from affiliates		(587.1	)						—			(587.1	)

Other (income) expense, net		3.6				50.2			50.2			(46.6	)

Income Before Taxes		1,967.3		(192.3	)	(93.8	)		(286.1	)		2,253.4

Taxes on Income		379.0							(80.1	)⁽³⁾		459.1

Net Income		1,588.3							(206.0	)		1,794.3

Less: Net Income Attributable to Noncontrolling Interests		32.0							—			32.0

Net Income Attributable to Merck & Co., Inc.	$	1,556.3						$	(206.0	)	$	1,762.3

Earnings per Common Share Assuming Dilution	$	0.74						$	(0.09	)	$	0.83	⁽⁴⁾

Average Shares Outstanding Assuming Dilution		2,110.0										2,110.0

Tax Rate		19.3	%									20.4	%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors understanding of the company’s performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1)	Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be sold or closed.

(2)	Merger-related costs include transaction and integration costs associated with the merger.

(3)	Represents the estimated tax impact on the reconciling items.

(4)

The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders. Net income attributable to Merck & Co., Inc. common shareholders used to calculate non-GAAP earnings per common share assuming dilution was $1,756.9 million for the second quarter of 2009.

MERCK & CO., INC.

CONSOLIDATED STATEMENT OF OPERATIONS

GAAP TO NON-GAAP RECONCILIATION

SIX MONTHS ENDED JUNE 30, 2009

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 2d


	GAAP			Restructuring Costs ⁽¹⁾		Merger-Related Costs ⁽²⁾		Adjustment Subtotal			Non-GAAP
Sales	$	11,285.1						$	—		$	11,285.1

Materials and production		2,687.7		69.3					69.3			2,618.4

Marketing and administrative		3,362.5				50.2			50.2			3,312.3

Research and development		2,619.5		195.9					195.9			2,423.6

Restructuring costs		101.7		101.7					101.7			—

Equity income from affiliates		(1,173.0	)						—			(1,173.0	)

Other (income) expense, net		(63.6	)			62.7			62.7			(126.3	)

Income Before Taxes		3,750.3		(366.9	)	(112.9	)		(479.8	)		4,230.1

Taxes on Income		706.2							(137.1	)⁽³⁾		843.3

Net Income		3,044.1							(342.7	)		3,386.8

Less: Net Income Attributable to Noncontrolling Interests		62.8							—			62.8

Net Income Attributable to Merck & Co., Inc.	$	2,981.3						$	(342.7	)	$	3,324.0

Earnings per Common Share Assuming Dilution	$	1.41						$	(0.16	)	$	1.57	⁽⁴⁾

Average Shares Outstanding Assuming Dilution		2,109.8										2,109.8

Tax Rate		18.8	%									19.9	%

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

(1)	Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be sold or closed.

(2)	Merger-related costs include transaction and integration costs associated with the merger.

(3)	Represents the estimated tax impact on the reconciling items.

(4)

MERCK & CO., INC.

FRANCHISE / KEY PRODUCT SALES

SECOND QUARTER 2010

(AMOUNTS IN MILLIONS)

Table 3b

The following Table reflects Supplemental Combined Non-GAAP sales which are adjusted to reflect a full quarter of Merck and Schering-Plough combined results as if the merger closed as of January 1, 2009.


	Global					U.S.					International
	2Q10		Supp. Comb. Non-GAAP 2Q09		% Change	2Q10		Supp. Comb. Non-GAAP 2Q09		% Change	2Q10		Supp. Comb. Non-GAAP 2Q09		% Change
TOTAL SALES ⁽¹⁾	$	11,346	$	11,534	-2	$	4,864	$	5,288	-8	$	6,482	$	6,247	4


HUMAN HEALTH ⁽²⁾		9,776		9,956	-2		4,041		4,323	-7		5,736		5,633	2
Bone, Resp., Imm., & Dermatology
Singulair		1,258		1,257			830		823	1		427		434	-2
Remicade		669		565	18							669		565	18
Nasonex		338		321	5		196		183	7		142		138	3
Fosamax		241		277	-13		21		42	-48		220		236	-7
Clarinex		202		226	-11		60		74	-20		143		152	-6
Propecia		113		106	7		37		37	-1		77		69	11
Arcoxia		95		88	8							95		88	8
Asmanex		56		54	4		54		52	3		2		2	29

Cardiovascular
Zetia		564		556	1		308		323	-5		256		233	10
Vytorin		490		532	-8		263		314	-16		227		218	4
Integrilin		70		73	-4		65		68	-5		5		5	-1

Diabetes & Obesity
Januvia		600		462	30		380		348	9		220		115	92
Janumet		218		155	41		136		113	20		82		41	*

Infectious Disease
Isentress		267		172	55		130		88	49		137		85	61
PegIntron		185		215	-14		25		30	-16		159		185	-14
Primaxin		158		160	-2		32		32	1		125		128	-2
Cancidas		150		149	1		14		18	-22		135		130	4
Avelox		59		71	-17		55		67	-19		5		4	8
Invanz		83		71	17		43		37	17		40		34	18
Rebetol		55		67	-18					*		55		67	-18
Crixivan / Stocrin		48		56	-14		2		3	-41		46		53	-12

Mature Brands
Cozaar / Hyzaar		485		906	-46		63		332	-81		423		573	-26
Zocor		117		141	-17		9		9	-1		108		132	-18
Claritin Rx		93		96	-3							93		96	-3
Vasotec / Vaseretic		63		76	-18							63		76	-18
Proscar		56		79	-30		2		1	15		54		78	-31
Proventil		55		56	-2		53		55	-4		2		1	79

Neurosciences & Ophthalmology
Maxalt		133		141	-5		93		99	-6		40		42	-4
Cosopt / Trusopt		123		125	-1		4		11	-61		119		114	5
Subutex / Suboxone		51		52	-2							51		52	-2
Remeron		59		50	17		2		2	-8		57		48	19

Oncology
Temodar		271		256	6		103		93	11		168		163	3
Emend		93		77	21		54		51	6		39		26	52
Caelyx		66		68	-3							66		68	-3
Intron A		51		67	-24		29		35	-17		22		32	-32

Vaccines
ProQuad, M-M-R II and Varivax		340		322	5		323		303	6		17		19	-13
Gardasil		219		268	-18		163		184	-12		56		84	-33
RotaTeq		139		126	10		118		107	10		21		18	15
Zostavax		18		42	-57		18		42	-57
Pneumovax		59		47	26		49		39	24		11		8	33

Women’s Health & Endocrine
NuvaRing		145		129	12		88		79	11		57		50	14
Follistim / Puregon		137		145	-5		43		49	-12		94		96	-2
Cerazette		49		46	7							49		46	7
Implanon		51		43	17		19		15	24		32		28	14

Other Human Health ⁽³⁾		986		965	2		158		166	-4		827		801	3

ANIMAL HEALTH		731		672	9		153		149	3		578		524	10

CONSUMER CARE ⁽²⁾		422		381	11		381		347	10		41		34	20
Claritin OTC		132		108	23		124		102	21		8		6	44

Other Revenues ⁽⁴⁾		417		524	-20		290		469	-38		127		55	*
Astra		241		386	-38		241		386	-38

⁽¹⁾	Only select products are shown.

⁽²⁾	Human Health includes worldwide prescription pharmaceutical sales and consumer product sales excluding the US and Canada. Consumer Care includes US and Canada consumer product sales.

⁽³⁾	Includes Human Health products not individually shown above. Other Vaccine sales included in Other Human Health were $57 million and $34 million on a global basis for second quarter 2010 and 2009, respectively.

⁽⁴⁾	Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

Note: The company is providing Supplemental Combined Non-GAAP sales to reflect the revenues of the company’s product sales on a comparable basis to periods prior to the merger. Merck has defined Supplemental Combined Non-GAAP sales as GAAP sales adjusted to reflect a full quarter of Merck and Schering-Plough performance as if the merger closed at the beginning of the periods indicated in this table. This supplemental information is provided to enhance investors’ understanding of the company’s sales performance. This information should be considered in addition to, but not in lieu of, sales reported in accordance with GAAP.

*	100% or over

MERCK & CO., INC.

FRANCHISE / KEY PRODUCT SALES

JUNE YEAR-TO-DATE 2010

(AMOUNTS IN MILLIONS)

Table 3c

The following Table reflects Supplemental Combined Non-GAAP sales which are adjusted to reflect the period of Merck and Schering-Plough combined results as if the merger closed as of January 1, 2009.


	Global					U.S.					International
	Jun YTD 2010		Supp. Comb. Non-GAAP Jun YTD 2009		% Change	Jun YTD 2010		Supp. Comb. Non-GAAP Jun YTD 2009		% Change	Jun YTD 2010		Supp. Comb. Non-GAAP Jun YTD 2009		% Change
TOTAL SALES ⁽¹⁾	$	22,768	$	22,217	2	$	9,862	$	10,233	-4	$	12,907	$	11,983	8


HUMAN HEALTH ⁽²⁾		19,570		19,191	2		8,130		8,360	-3		11,439		10,832	6
Bone, Resp., Imm., & Dermatology
Singulair		2,423		2,315	5		1,559		1,505	4		864		809	7
Remicade		1,343		1,083	24							1,343		1,083	24
Nasonex		658		627	5		351		340	3		307		286	7
Fosamax		472		539	-12		47		82	-43		425		456	-7
Clarinex		376		400	-6		109		134	-19		267		266	1
Propecia		213		209	2		72		73	-1		141		136	4
Arcoxia		190		169	12							190		169	12
Asmanex		107		103	4		103		99	4		4		4	-2

Cardiovascular
Zetia		1,098		1,067	3		588		633	-7		509		434	17
Vytorin		967		1,010	-4		518		601	-14		449		408	10
Integrilin		140		149	-6		130		140	-7		10		9	2

Diabetes & Obesity
Januvia		1,111		873	27		734		661	11		377		213	77
Janumet		419		283	48		261		214	22		158		69	*

Infectious Disease
Isentress		499		320	56		241		163	49		258		158	63
PegIntron		371		430	-14		51		59	-13		320		372	-14
Primaxin		317		324	-2		67		62	9		249		262	-5
Cancidas		303		287	5		29		37	-20		273		250	9
Avelox		165		180	-9		156		172	-9		9		8	8
Invanz		158		132	19		81		70	16		77		62	23
Rebetol		111		134	-17					-13		111		133	-17
Crixivan / Stocrin		100		105	-5		4		6	-26		95		99	-4

Mature Brands
Cozaar / Hyzaar		1,267		1,745	-27		354		636	-44		913		1,109	-18
Zocor		233		278	-16		19		18	9		214		261	-18
Claritin Rx		217		228	-5							217		228	-5
Vasotec / Vaseretic		122		153	-21							122		153	-21
Proscar		114		151	-25		3		3	15		111		149	-25
Proventil		112		110	2		109		108			3		1	*

Neurosciences & Ophthalmology
Maxalt		268		274	-2		176		191	-8		92		83	11
Cosopt / Trusopt		238		246	-3		10		25	-61		228		221	3
Subutex / Suboxone		104		102	1							104		102	1
Remeron		110		100	10		3		4	-21		106		96	11

Oncology
Temodar		545		503	8		195		185	6		350		318	10
Emend		177		146	21		105		95	11		71		51	40
Caelyx		139		128	8							139		128	8
Intron A		105		121	-13		59		62	-3		46		59	-23

Vaccines
ProQuad, M-M-R II and Varivax		659		574	15		619		538	15		40		37	9
Gardasil		451		530	-15		319		363	-12		133		167	-20
RotaTeq		231		260	-11		191		232	-17		40		28	41
Zostavax		114		118	-3		114		118	-3
Pneumovax		110		88	25		89		69	29		21		19	12

Women’s Health & Endocrine
NuvaRing		280		244	15		171		151	13		109		93	17
Follistim / Puregon		270		275	-2		84		92	-8		186		184	1
Cerazette		104		85	22							104		85	22
Implanon		101		80	26		38		28	34		63		52	21

Other Human Health ⁽³⁾		1,960		1,910	3		369		390	-5		1,590		1,520	5

ANIMAL HEALTH		1,440		1,293	11		293		294			1,147		999	15

CONSUMER CARE ⁽²⁾		800		765	5		718		700	3		82		65	25
Claritin OTC		242		257	-6		226		246	-8		16		11	47

Other Revenues ⁽⁴⁾		959		967	-1		721		880	-18		237		86	*
Astra		605		742	-19		605		742	-19

⁽¹⁾	Only select products are shown.

⁽²⁾	Human Health includes worldwide prescription pharmaceutical sales and consumer product sales excluding the US and Canada. Consumer Care includes US and Canada consumer product sales.

⁽³⁾	Includes Human Health products not individually shown above. Other Vaccine sales included in Other Human Health were $113 million and $83 million on a global basis for second quarter 2010 and 2009, respectively.

⁽⁴⁾	Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

Note: The company is providing Supplemental Combined Non-GAAP sales to reflect the revenues of the company’s product sales on a comparable basis to periods prior to the merger. Merck has defined Supplemental Combined Non-GAAP sales as GAAP sales adjusted to reflect the period of Merck and Schering-Plough performance as if the merger closed at the beginning of the periods indicated in this table. This supplemental information is provided to enhance investors’ understanding of the company’s sales performance. This information should be considered in addition to, but not in lieu of, sales reported in accordance with GAAP.

MERCK & CO., INC.

HUMAN HEALTH GEOGRAPHIC SALES

(AMOUNTS IN MILLIONS)

Table 3d


	1Q10			2Q10			Jun YTD

TOTAL HUMAN HEALTH	$	9,793		$	9,776		$	19,570


United States		4,090			4,041			8,130
% Human Health Sales		41.8	%		41.3	%		41.5	%

Europe ⁽¹⁾		2,831			2,660			5,491
% Human Health Sales		28.9	%		27.2	%		28.1	%

Japan		811			902			1,712
% Human Health Sales		8.3	%		9.2	%		8.7	%

Latin America		694			728			1,422
% Human Health Sales		7.1	%		7.4	%		7.3	%

Asia Pacific		587			659			1,245
% Human Health Sales		6.0	%		6.7	%		6.4	%

Eastern Europe/Middle East Africa		404			422			826
% Human Health Sales		4.1	%		4.3	%		4.2	%

Canada		337			328			665
% Human Health Sales		3.4	%		3.4	%		3.4	%

Other		39			37			77
% Human Health Sales		0.4	%		0.4	%		0.4	%

(1)	Europe primarily represents all European Union countries and the European Union accession markets.

MERCK & CO., INC.

FRANCHISE / KEY PRODUCT SALES

June 2010

(AMOUNTS IN MILLIONS)

Table 3e


	2010 - GAAP
	1Q		2Q		June YTD
TOTAL SALES ⁽¹⁾	$	11,422	$	11,346	$	22,768


HUMAN HEALTH ⁽²⁾		9,793		9,776		19,570

Bone, Resp., Imm., & Dermatology
Singulair		1,165		1,258		2,423
Remicade		674		669		1,343
Nasonex		320		338		658
Fosamax		230		241		472
Clarinex		174		202		376
Propecia		100		113		213
Arcoxia		95		95		190
Asmanex		51		56		107

Cardiovascular
Zetia		534		564		1,098
Vytorin		477		490		967
Integrilin		70		70		140

Diabetes & Obesity
Januvia		511		600		1,111
Janumet		201		218		419

Infectious Disease
Isentress		232		267		499
PegIntron		186		185		371
Primaxin		159		158		317
Cancidas		153		150		303
Avelox		106		59		165
Invanz		75		83		158
Rebetol		56		55		111
Crixivan / Stocrin		52		48		100

Mature Brands
Cozaar / Hyzaar		782		485		1,267
Zocor		116		117		233
Claritin Rx		124		93		217
Vasotec / Vaseretic		59		63		122
Proscar		58		56		114
Proventil		57		55		112

Neurosciences & Ophthalmology
Maxalt		135		133		268
Cosopt / Trusopt		115		123		238
Subutex / Suboxone		52		51		104
Remeron		51		59		110

Oncology
Temodar		274		271		545
Emend		84		93		177
Caelyx		74		66		139
Intron A		54		51		105

Vaccines
ProQuad, M-M-R II and Varivax		319		340		659
Gardasil		233		219		451
RotaTeq		93		139		231
Zostavax		95		18		114
Pneumovax		51		59		110

Women’s Health & Endocrine
NuvaRing		135		145		280
Follistim / Puregon		134		137		270
Cerazette		55		49		104
Implanon		51		51		101

Other Human Health ⁽³⁾		974		986		1,960

ANIMAL HEALTH		709		731		1,440

CONSUMER CARE ⁽²⁾		379		422		800
Claritin OTC		110		132		242

Other Revenues ⁽⁴⁾		542		417		959
Astra		364		241		605

⁽¹⁾	Only select products are shown.

⁽²⁾	Human Health includes worldwide prescription pharmaceutical sales and consumer product sales excluding the US and Canada. Consumer Care includes US and Canada consumer product sales.

⁽³⁾	Includes Human Health products not individually shown above. Other vaccines sales included in Other Human Health were $55 million and $57 million for first and second quarters of 2010, respectively.

⁽⁴⁾	Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

MERCK & CO., INC.

FRANCHISE / KEY PRODUCT SALES-SUPPLEMENTAL COMBINED NON-GAAP

FULL YEAR 2009

(AMOUNTS IN MILLIONS)

Table 3f

The following Table reflects Supplemental Combined Non-GAAP sales which are adjusted to reflect full quarters and a full year of Merck and Schering-Plough combined results as if the merger closed as of January 1, 2009.


	2009 - Supplemental Combined Non-GAAP
	1Q		2Q		3Q		4Q		Full Year
TOTAL SALES ⁽¹⁾	$	10,683	$	11,534	$	11,531	$	12,216	$	45,964

HUMAN HEALTH ⁽²⁾		9,235		9,956		10,101		10,805		40,098

Bone, Resp., Imm., & Dermatology
Singulair		1,057		1,257		1,085		1,260		4,660
Remicade		518		565		608		635		2,327
Nasonex		306		321		266		286		1,179
Fosamax		261		277		276		285		1,100
Clarinex		174		226		164		155		719
Propecia		103		106		109		123		440
Arcoxia		81		88		90		98		358
Asmanex		49		54		53		58		214

Cardiovascular
Zetia		510		556		563		614		2,244
Vytorin		477		532		525		577		2,112
Integrilin		76		73		74		72		295

Diabetes & Obesity
Januvia		411		462		491		558		1,922
Janumet		128		155		173		202		658

Infectious Disease
PegIntron		216		215		198		216		844
Isentress		148		172		197		234		752
Primaxin		165		160		168		196		689
Cancidas		139		149		155		175		617
Avelox		109		71		70		118		368
Invanz		62		71		73		88		293
Rebetol		66		67		64		57		254
Crixivan / Stocrin		49		56		49		52		206

Mature Brands
Cozaar / Hyzaar		839		906		861		955		3,561
Zocor		137		141		141		139		558
Claritin Rx		132		96		95		109		433
Vasotec / Vaseretic		77		76		73		85		311
Proscar		72		79		67		72		291
Proventil		54		56		59		56		225

Neurosciences & Ophthalmology
Maxalt		133		141		144		156		575
Cosopt / Trusopt		121		125		123		134		503
Remeron		50		50		74		60		234
Subutex / Suboxone		50		52		53		56		211

Oncology
Temodar		247		256		278		292		1,073
Emend		69		77		82		89		317
Caelyx		61		68		67		70		265
Intron A		54		67		56		54		231

Vaccines
ProQuad, M-M-R II and Varivax		252		322		462		333		1,369
Gardasil		262		268		311		277		1,118
RotaTeq		134		126		127		135		522
Pneumovax		41		47		130		128		346
Zostavax		75		42		84		76		277

Women’s Health & Endocrine
Follistim / Puregon		131		145		122		149		546
NuvaRing		115		129		131		135		511
Cerazette		39		46		49		53		187
Implanon		37		43		45		53		179

Other Human Health ⁽³⁾		945		965		1,016		1,079		4,005

ANIMAL HEALTH		621		672		664		759		2,716

CONSUMER CARE ⁽²⁾		384		381		283		232		1,281
Claritin OTC		149		108		85		63		406

Other Revenues ⁽⁴⁾		443		524		483		420		1,870
Astra		356		386		340		332		1,414

⁽¹⁾	Only select products are shown.

⁽²⁾	Human Health includes worldwide prescription pharmaceutical sales and consumer product sales excluding the US and Canada. Consumer Care includes US and Canada consumer product sales.

⁽³⁾	Includes Human Health products not individually shown above. Other vaccines sales included in Other Human Health were $50M in 1Q09, $34M in 2Q09, $54M in 3Q09, and $50M in 4Q09, respectively.

⁽⁴⁾	Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

Note: The company is providing Supplemental Combined Non-GAAP sales to reflect the revenues of the company’s product sales on a comparable basis to periods prior to the merger. Merck has defined Supplemental Combined Non-GAAP sales as GAAP sales adjusted to reflect a full year of Merck and Schering-Plough performance as if the merger closed at the beginning of the periods indicated in this table. This supplemental information is provided to enhance investors’ understanding of the company’s sales performance. This information should be considered in addition to, but not in lieu of, sales reported in accordance with GAAP.

MERCK & CO., INC.

EQUITY INCOME / JV SALES / OTHER (INCOME) EXPENSE-GAAP

SECOND QUARTER 2010

Table 4

EQUITY INCOME FROM AFFILIATES (millions of dollars)


	2Q10		2Q09		YTD 2010		YTD 2009
ASTRAZENECA LP	$	40.1	$	122.9	$	165.1	$	291.2
MERCK / SCHERING-PLOUGH ⁽¹⁾		—		362.3		—		653.2
Other ⁽²⁾		2.8		101.9		15.3		228.6

TOTAL	$	42.9	$	587.1	$	180.4	$	1,173.0

⁽¹⁾	Upon completion of the merger with Schering-Plough, the Merck/Schering-Plough partnership became wholly-owned by the company.

⁽²⁾	Primarily reflects results for Merial Limited (which was disposed of on September 17, 2009), Sanofi Pasteur MSD and Johnson & JohnsonºMerck Consumer Pharmaceuticals.

SANOFI PASTEUR MSD JOINT VENTURE SALES DETAIL (millions of dollars)

All sales reported here are end-market JV sales, presented on a “NET” basis.


	2Q10		2Q09		YTD 2010		YTD 2009
GARDASIL	$	82.3	$	144.9	$	164.5	$	309.0
OTHER VIRAL VACCINES		23.4		26.9		46.4		52.3
ROTATEQ		13.8		10.1		25.4		18.8
FLU VACCINES		—		—		10.0		—
HEPATITIS VACCINES		5.7		11.0		11.6		24.4
Other Vaccines		112.2		120.3		230.6		252.0

TOTAL SANOFI PASTEUR MSD SALES	$	237.4	$	313.2	$	488.5	$	656.5

OTHER (INCOME) EXPENSE, NET (millions of dollars)


	2Q10			2Q09			YTD 2010			YTD 2009
INTEREST INCOME	$	(21.6	)	$	(70.0	)	$	(33.6	)	$	(166.3	)
INTEREST EXPENSE		184.8			99.5			366.0			160.2
EXCHANGE (GAINS) LOSSES		(4.3	)		(20.0	)		75.8			(3.5	)
Other, net		(439.3	)		(5.9	)		(520.9	)		(54.0	)

TOTAL	$	(280.4	)	$	3.6		$	(112.7	)	$	(63.6	)